The European Medicines Agency (EMEA) has recently approved a new indication for Procoralan*(ivabradine). Procoralan can now be administered to chronic stable angina patients, who remain inadequately controlled despite an optimal dose of beta blockers, and whose heart rate is above 60 beats per minute.
The details can be read here.
No comments:
Post a Comment